期刊文献+

定量检测血小板特异性抗体的流式免疫微珠芯片技术的建立及其临床应用 被引量:1

Establishment of Flow Cytometric Immunobead Array Assay for Quantitation of Platelet-Specific Antibodies and Its Application
下载PDF
导出
摘要 目的:建立流式免疫微珠芯片技术(FCIA)定量检测血小板特异性抗体的方法,探讨其在ITP诊治中的应用。方法:通过已知浓度的人IgG结合在包被抗体的微珠上,构建定量标准曲线,同时使用5种抗血小板GPIX(SZ1)、GPIb(SZ2)、GPIIIa(SZ21)、GPIIb(SZ22)和P-选择素(SZ51)抗体包被的微珠捕获血小板特异性抗原抗体复合物进行血小板抗体的检测。通过定量标准曲线将流式细胞仪检测的荧光信号转换成样品中血小板抗体浓度,从而建立定量检测血浆样品中血小板特异性抗体的方法(FCIA),并对该方法从性能、效率,临床应用等方面进行评价。结果:针对GPIX、GPIb、GPIIIa、GPIIb和P-选择素5种抗体的FCIA定量检测范围分别为33.29-1280、45.17-1280、42.07-1280、46.40-1280和42.48-1280 ng/ml,回收率分别为115.23%、112.58%、117.47%、107.64%和112.67%。批内精密度(CV%)分别为3.54%、3.65%、4.66%、6.43%和6.97%,批间精密度(CV%)分别为10.89%、7.57%、10.34%、6.95%和10.72%。ITP组5种血小板特异性抗体浓度值均高于NITP和健康对照组(P<0.01)。FCIA定量检测5种抗体对诊断ITP的灵敏度、特异性和准确度分别为68.29%,84.93%和78.95%,而改良间接MAIPA技术检测的相应值分别为41.46%、90.41%和72.81%。结论:建立的血小板特异性抗体FCIA定量检测方法为ITP的诊断、疗效评估、患者预后提供了一个良好工具。 Objective:To establish a flow cytometric immunobead array assay(FCIA)to quantify platelet antibodies and to explore its application in the diagnosis and treatment of ITP.Methods:The guantitative standard curve was established by binding the human IgG of known concentration on antibody-coated microbeads;at the same time,the platelet-specific antigen and antibody complex was captured and levels of platelet antibodies were detected using the microbeads coated by 5 kinds of antibodies against platelets suca as GPⅨ(SZ1),GPⅠb(SZ2),GpⅢa(SZ21),GPⅡb(SZ22)and p-selection(SZ51).The fluorescence signal detected by flow cytometry were transformed into the conentration of platelet antibodies in samples through the quantitative standard curve,thereby establishing the method for quantititive detection of platelet-specific antibodies in plasm samples(FCIA),moreover the property,efficiency and clinical application of established FCIA method were evaluated.Results:The FCIA could detect 5 kinds of antibodies against GPⅨ,GPⅠb,GpⅢa,GPⅡb andβ-selection within a broad range of 33.29-1280 ng/ml,45.17-1280 ng/ml,42.07-1280 ng/ml,46.40-1280 ng/ml,42.48-1280 ng/ml and 42.48-1280 ng/ml respectively,and their recovery rates were 115.23%,112.58%,117.47%,107.64%and 112.67%respectively.The intra-assay coefficient of variation(CV)for anti-GPⅨ,-GPⅠb,-GpⅢa,-GPⅡb and p-selection antibodies was 3.54%,3.63%,4.66%,6.43%and 6.67%respectively,and the inter-assay CV for above mentioned antibodies were 10.89%,7.57%,10.34%,6.95%and 10.72%respectively.The detection showed that the levels of 5 kinds of platelet-specific antibodies in ITP group all were higher than those in non-ITP and healthy control groups(P<0.01).The sensitivity,specificity and accuracy of quantitatively detecting 5 kinds of antibodies for diagnosis of ITP by FCIA were 68.29%,84.98%and 78.95%respectively,while the sensitivity,specificity and accuracy of detecting 5 kinds of antibodies by modified indirect MAIPA were 41.46%,90.41%and72.81%respectively.Conclusion:The established quantitative FCIA for detection of antibodies provides a powerful tool for diaghosis and evaluation of therapeutic efficacy and prognosis of ITP patients.
作者 翟菊萍 左斌 翁震 赵赟霄 何杨 ZHAI Ju-Ping;ZUO Bin;WENG Zhen;ZHAO Yun-Xiao;HE Yang(Department of Blood Transfusion,The First Affiliated Hospital of Soochow University;Jiangsu provincial Institute of Hematology,Ministry of Health Key Laboratory of Thrombosis and Hemostasis,Suzhou 215006,Jiangsu Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2019年第6期1955-1961,共7页 Journal of Experimental Hematology
关键词 血小板特异性抗体 免疫微珠芯片技术 定量流式细胞术 ITP platelet-specific antibody immunobead array assay quantitative flow cytometry ITP
  • 相关文献

参考文献1

二级参考文献8

  • 1张建,王爱华,顾鹏飞,于嘉屏.人线粒体肌酸激酶广泛型亚型的原核表达、抗体制备及其临床应用意义[J].第二军医大学学报,2004,25(12):1320-1324. 被引量:4
  • 2Schlattner U, Tokarska-Schlattner M, Wallimann T.Mitochondrial creatine kinase in human health and disease [ J ]. Biochim Biophys Acta, 2006,1762 ( 2 ) : 164-180.
  • 3Kanemitsu F, Kawanishi I, Mizushima J, et al. Mito- chondrial creatine kinase as a tumor-associated marker [J]. Clin Chim Acta, 1984, 138(2) :175-183.
  • 4Pratt R, Vallis LM, Lim CW, et al. Mitochondrial creatine kinase in cancer patients [ J ]. Pathology, 1987, 19(2) :162-165.
  • 5Lee YC, Chang K J, Lu FJ, et al. Serum macro creatine kinase type 2 as a tumor marker in lung cancer: comparison with carcinoembryonic antigen [J]. J Formos Med Assoc, 1990, 89(2) :104-109.
  • 6Kornacker M, Schlattner U, Wallimann T, et al. Hodgkin disease-derived cell lines expressing ubiqui- tous mitochondrial creatine kinase show growth inhibi- tion by cyclocreatine treatment independent of apopto- sis[J]. Int J Cancer, 2001,94(4) :513-519.
  • 7Qian XL, Li YQ, Gu F, et al. Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prog- nosis in breast cancer patients [ J ]. Biochem Biophys Res Commun,2012,427( 1 ) :60-66.
  • 8Hatano E, Tanaka A, Kanazawa A, et al. Inhibition of tumor necrosis factor-induced apoptosis in trans- genic mouse liver expressing creatine kinase [ J ]. Liver Int,2004,24 (4) :384-393.

共引文献3

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部